D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Academic Article uri icon

Overview

MeSH

  • Adult
  • Aged
  • Anger
  • Chemotherapy, Adjuvant
  • Chronic Disease
  • Depression
  • Double-Blind Method
  • Extinction, Psychological
  • Fear
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Psychiatric Status Rating Scales
  • Sleep
  • Time Factors
  • Treatment Outcome

MeSH Major

  • Cycloserine
  • Implosive Therapy
  • Psychotropic Drugs
  • Stress Disorders, Post-Traumatic

abstract

  • Viewing post-traumatic stress disorder (PTSD) as a disorder of emotional learning, this study used a cognitive enhancer synergistically with virtual reality exposure (VRE) therapy for the treatment of PTSD. The main objective was to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the efficacy of the psychotherapy. Pre-clinical studies suggest that when fear extinction occurs during DCS administration, neuroplasticity may be enhanced. VRE therapy is a particularly promising format to test the hypothesis that DCS enhances extinction learning, as sensory fear cues are standardized across patients. In a pilot randomized, double-blind, placebo-controlled trial, 100 mg of DCS or placebo was administered 90 min before each weekly VRE session, to ensure peak plasma concentrations during the sessions in 25 patients with chronic PTSD. The primary outcome measure was the Clinician Administered PTSD Scale (CAPS). Secondary outcome measures included the Beck Depression Inventory-II and the State-Trait Anger Expression Inventory-2. Assessments occurred at pre-treatment, following sessions 3, 6, 10, post-treatment, and at 6 months. The difference in CAPS between the VRE-DCS (n=13) and VRE-placebo (n=12) groups increased over time beginning at 6 weeks, with medium to large between-group effect sizes immediately post-treatment and 6 months later (d=0.68 and d=1.13, respectively). A similar pattern was observed for depression, anger expression, and sleep. PTSD remission rates were significantly greater for the VRE-DCS group (46% vs 8% at post-treatment; 69% vs 17% at 6 months). Patients in the VRE-DCS group showed earlier and greater improvement in PTSD symptoms compared with the VRE-placebo group. These results suggest a promising new treatment for PTSD.

publication date

  • April 2014

has subject area

  • Adult
  • Aged
  • Anger
  • Chemotherapy, Adjuvant
  • Chronic Disease
  • Cycloserine
  • Depression
  • Double-Blind Method
  • Extinction, Psychological
  • Fear
  • Female
  • Humans
  • Implosive Therapy
  • Male
  • Middle Aged
  • Pilot Projects
  • Psychiatric Status Rating Scales
  • Psychotropic Drugs
  • Sleep
  • Stress Disorders, Post-Traumatic
  • Time Factors
  • Treatment Outcome

Research

keywords

  • Journal Article
  • Randomized Controlled Trial

Identity

Language

  • eng

PubMed Central ID

  • PMC3957110

Digital Object Identifier (DOI)

  • 10.1038/npp.2013.317

PubMed ID

  • 24217129

Additional Document Info

start page

  • 1052

end page

  • 1058

volume

  • 39

number

  • 5